Vivos Therapeutics (VVOS) Capital Expenditures Growth (3y) (2023 - 2026)
Vivos Therapeutics (VVOS) Capital Expenditures Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 10.17% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 1.81% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 2.15% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 0.84% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 10.35% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 8.08% |
| 10 | Vivos Therapeutics | 7.39 Mn | 5.16 Mn | 3.06 Mn | -28.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.86% |
| Dec 31, 2025 | 179.67% |
| Sep 30, 2025 | -41.45% |
| Jun 30, 2025 | 15.22% |
| Mar 31, 2025 | 0.55% |
| Dec 31, 2024 | 27.79% |
| Sep 30, 2024 | -24.21% |
| Jun 30, 2024 | -64.23% |
| Mar 31, 2024 | -16.78% |
| Dec 31, 2023 | -194.54% |
| Sep 30, 2023 | 134.10% |
| Jun 30, 2023 | 281.72% |
| Mar 31, 2023 | 112.59% |